Welcome to our dedicated page for Ocugen news (Ticker: OCGN), a resource for investors and traders seeking the latest updates and insights on Ocugen stock.
Ocugen, Inc. develops gene therapies for blindness diseases through a modifier gene therapy platform designed to address inherited and multifactorial retinal disorders. Company news commonly covers programs such as OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy secondary to dry age-related macular degeneration, and OCU410ST for Stargardt disease.
Recurring updates include clinical trial data and dosing milestones, clinical and regulatory disclosures, operating and financial results, investor presentations, convertible-note financing, shareholder voting matters, capital-structure actions, and governance matters tied to the company's Nasdaq-listed common stock.
Ocugen Inc. (NASDAQ: OCGN), a biotechnology company specializing in gene and cell therapies and vaccines, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024 in New York. Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen, will engage in a fireside chat on Monday, September 9, 2024, at 1:30 p.m. ET at the Lotte New York Palace Hotel.
The event provides an opportunity for Ocugen to showcase its recent corporate achievements and upcoming milestones. Additionally, the company's executive team will conduct one-on-one meetings with registered investors to discuss Ocugen's business and clinical development strategy, particularly focusing on its unique modifier gene therapy platform.
A live video webcast of the presentation will be available on Ocugen's investor site, with a replay archived for 90 days following the event.
Ocugen (NASDAQ: OCGN) has completed dosing in the third cohort of its Phase 1/2 GARDian clinical trial for OCU410ST, a modifier gene therapy for Stargardt disease. The trial, conducted at six U.S. retinal surgery centers, has finished Phase 1 of the dose-escalation portion. Three subjects received the highest dose (2.25×1011 vg/mL) via subretinal injection. The GARDian trial aims to assess safety and efficacy of OCU410ST in Stargardt patients, who currently lack FDA-approved treatments. Dr. Charles Wykoff, lead investigator, noted an encouraging safety and tolerability profile. The trial includes three dose levels, and Ocugen plans to provide periodic clinical updates as it advances this potential one-time treatment option.
Ocugen (NASDAQ: OCGN) has received approval from Health Canada to initiate a Phase 3 clinical trial for OCU400, its modifier gene therapy for retinitis pigmentosa (RP). The trial, named liMeliGhT, will run parallel to the U.S. FDA trial, potentially expediting a gene-agnostic treatment option for approximately 110,000 patients in the U.S. and Canada.
The study will enroll up to 50 subjects across 5 Canadian sites, targeting patients aged 8 and older with various stages of RP. The primary endpoint is the change in functional vision measured by the Luminance Dependent Navigation Assessment (LDNA). OCU400 has received orphan drug and RMAT designations from the FDA, with 2026 BLA and MAA approval targets.
Ocugen (NASDAQ: OCGN) reported its Q2 2024 financial results and provided a business update. Key highlights include:
- Active dosing in OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa
- Progression to Phase 2 of OCU410 ArMaDa clinical trial for geographic atrophy
- Expanded access program approved for OCU400
- $32.6 million net cash from public offering of common stock
The company's cash position was $16.0 million as of June 30, 2024. Total operating expenses for Q2 2024 were $16.6 million, with a net loss of $0.04 per share. Ocugen continues to advance its gene therapy pipeline and expects OCU410 preliminary safety and efficacy data later this year.
Ocugen, Inc. (NASDAQ: OCGN) has received FDA approval to begin an expanded access program (EAP) for OCU400, its modifier gene therapy candidate for retinitis pigmentosa (RP). The EAP will allow adult patients aged 18 and older with RP to access OCU400 outside of clinical trials. This development follows positive Phase 1/2 study data and an ongoing Phase 3 liMeliGhT clinical trial.
OCU400 has received orphan drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA. The European Medicines Agency (EMA) has also accepted the U.S.-based trial for submission of a Marketing Authorization Application (MAA). Ocugen aims for targeted BLA and MAA approval in 2026.
Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company focusing on gene and cell therapies and vaccines, has closed its public offering of 30,434,783 common stock shares at $1.15 per share. The offering, led by a premier mutual fund and prominent life sciences investors, raised approximately $35 million in gross proceeds. Titan Partners Group, a division of American Capital Partners, acted as the sole book-running manager.
The company plans to use the net proceeds for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. The offering was made pursuant to a previously filed and effective shelf registration statement on Form S-3.
Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company, has announced the pricing of its underwritten public offering of 30,434,783 shares of common stock at $1.15 per share. This offering is expected to generate gross proceeds of $35 million before deducting underwriting discounts, commissions, and other expenses. The company has also granted the underwriter a 30-day option to purchase up to 4,565,217 additional shares. The offering is set to close around August 2, 2024.
Ocugen plans to use the net proceeds for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. Titan Partners Group is acting as the sole book-running manager for this offering, which is being made pursuant to a shelf registration statement previously filed with the SEC.
Ocugen, Inc. (Nasdaq: OCGN), a biotechnology company, has announced a proposed public offering of common stock. The company plans to grant the underwriter a 30-day option to purchase up to an additional 15% of shares. Ocugen intends to use the net proceeds for general corporate purposes, capital expenditures, working capital, and general and administrative expenses. Titan Partners Group is acting as the sole book-running manager for the offering. The offering is being made pursuant to a shelf registration statement on Form S-3 filed with the SEC. A preliminary prospectus supplement and accompanying base prospectus will be available on the SEC's website.
Ocugen (NASDAQ: OCGN), a biotechnology company specializing in gene and cell therapies and vaccines, has announced a conference call and webcast scheduled for August 8, 2024, at 8:30 a.m. ET. The event will cover the company's second quarter 2024 financial results and provide a business update. Ocugen plans to release a pre-market earnings announcement on the same day.
Interested parties can join the call using the following details:
- U.S. callers: (800) 715-9871
- International callers: (646) 307-1963
- Conference ID: 7453742
Ocugen, Inc. (NASDAQ: OCGN) has completed dosing in the high-dose cohort of its Phase 1/2 ArMaDa clinical trial for OCU410, a novel modifier gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration (dAMD). The trial, conducted at 14 leading retinal surgery centers in the US, has finished the Phase 1 stage with three subjects receiving the highest dose. OCU410 aims to provide a one-time treatment option for GA, which affects approximately 1 million people in the United States.
The company has now initiated a Phase 2 clinical trial to assess the safety and efficacy of OCU410 in a larger patient group, randomized into medium-dose, high-dose, or control groups. This novel approach could potentially transform GA treatment, addressing limitations of current FDA-approved therapies that require continuous intravitreal injections over several years.